LOS ANGELES, CA --(Marketwired - January 25, 2016) - ITUS Corporation (" ITUS ") (
Robert Berman, ITUS's President and CEO, stated: "I recently had the privilege of meeting Dr. Baskies and had an opportunity to describe the early cancer detection platform we are developing and the progress we have made at Anixa. With the recently renewed national commitment to cancer research and our focus on early cancer detection, this is a very exciting time for our company. We are pleased that Dr. Baskies has agreed to give us time out of his enormously busy schedule and are honored to have him join our world class team of advisors."
Dr. Baskies commented: "As a result of my training and interests, I see many early stage technologies, and have a unique perspective to gauge the potential impact that new technologies would have on the lives of cancer patients. As a surgical oncologist, I have firsthand knowledge of the benefits that effective early cancer detection would have on the types of surgeries that I have performed throughout my career. I am convinced that accurate and affordable early cancer screening and detection with new technologies, such as the platform being developed by Anixa, would be enormously helpful in improving treatment outcomes and cancer survival rates, and I hope that my knowledge and resources can assist Anixa in making their tests successful."
Dr. Baskies is a fellowship trained surgical oncologist, with special interests in breast cancer, thyroid cancer, and melanoma. He received his Bachelor of Arts degree, summa cum laude, and was a member of Phi Beta Kappa at Boston University, graduated from the Boston University School of Medicine, completed his surgical residency at Boston Medical Center, and received a fellowship in surgical oncology at the National Cancer Institute.
Anixa is developing a platform for blood tests for the early detection of solid tumor based cancers.
ITUS Corporation
ITUS Corporation funds and develops emerging technologies. The Company's subsidiary, Anixa Diagnostics Corporation, is developing a platform for non-invasive early cancer detection blood tests. Additional information is available at www.ITUScorp.com .
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will," and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may case our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2015, as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
ITUS Corporation: FOCUSED ON INNOVATION™
Contact: Dean Krouch 310-484-5184 dkrouch@ITUScorp.com
